Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301416 · ClinicalTrials.gov registry record · Phase 2
Qsymia as an Adjunct to Surgical Therapy in the Superobese
A Phase 2 study of Obesity and Weight Loss, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02301416 is a Phase 2 study of Obesity and Weight Loss that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02301416, a Phase 2 study of Obesity and Weight Loss, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication.
Conditions Studied
Interventions
- DRUG Phentermine/topiramate
- OTHER low calorie diet
Study Locations (1)
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301416
The ClinicalTrials.gov registry entry for NCT02301416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Phentermine/topiramate is the first listed.
NCT02301416 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02301416 about?
NCT02301416 is a clinical study titled "Qsymia as an Adjunct to Surgical Therapy in the Superobese". This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication.
What is the current status of trial NCT02301416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-12. Estimated completion is 2018-06-27.
What conditions does trial NCT02301416 study?
This clinical trial studies the following conditions: Obesity, Weight Loss, Metabolic Surgery, Bariatric Surgery Procedures.
What interventions are being tested in trial NCT02301416?
The interventions under investigation include: Phentermine/topiramate (DRUG), low calorie diet (OTHER).
Who is sponsoring clinical trial NCT02301416?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301416 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.